Sprache auswählen
PTH1R
PTH1R Molekülinformation
| Englischer Name | Parathyroid hormone receptor | Anzahl der inverkehr gebrachten Arzneimittel | 23 |
| Anzahl der klinischen Arzneimittel | 25 | Target-Alias | Receptors， Parathyroid Hormone |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Parathyroid hormone receptor |
| Target-Alias | Receptors， Parathyroid Hormone |
| Anzahl der inverkehr gebrachten Arzneimittel | 23 |
| Anzahl der klinischen Arzneimittel | 25 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
PTH1R Produktliste
- Attribut
Protein (2)Cell (1)
- Produktbibliothek
Online (3)
- Spezies
Human (3)
- Etikett
His Tag (1)- (2)
- Marker
Unconjugated (2)- (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
CHEK-ATF194 |  Human | HEK293 | Human PTH1R (Luc) HEK293 Reporter Cell |  |  In den Warenkorb legen | ||
PTR-H5222 | Human | HEK293 | Human PTH1R / PTHR1 Protein, His Tag, low endotoxin (MALS verified) |  |  |  | In den Warenkorb legen |
PTR-H52P3 | Human | HEK293 | Human PTH1R Full Length Protein (VLP) | | In den Warenkorb legen |
Gesamtmenge3
- 1
PTH1R Molekülhintergrund
Parathyroid hormone/parathyroid hormone-related peptide receptor is also known as Parathyroid hormone 1 receptor (PTH1R), PTHR1, PTH/PTHrP type I receptor (PTH/PTHr receptor), which belongs to the G-protein coupled receptor 2 family. PTH1R / PTHR1 is a receptor for parathyroid hormone and for parathyroid hormone-related peptide. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system.
PTH1R Molekülalias
PTH1R,PTHR,PTHR1
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Teriparatide biosimilar (National Institute of Dental and Craniofacial Research) | rhPTH (1-34) (National Institute of Dental and Craniofacial Research) | Phase 3 Clinical | National Institute Of Dental And Craniofacial Research | DiGeorge Syndrome; Hypoparathyroidism; Hypothyroidism | Details |
| Teriparatide biosimilar (Shanghai CAS Shenglongda Biotech) | Phase 3 Clinical | Shanghai Zhongke Shenglongda Biotechnology (Group) Co Ltd | Osteoporosis, Postmenopausal | Details | |
| Parathyroid hormone 1-84 (Kerun Biopharmaceutical) | Phase 3 Clinical | Chongqing Kerun Biologic Pharmaceutical Development Co Ltd | Hypoparathyroidism; Osteoporosis, Postmenopausal | Details | |
| MT-1013 | MT-1013 | Phase 3 Clinical | Shaanxi Micot Pharmaceutical Technology Co Ltd | Hyperparathyroidism; Hyperparathyroidism, Secondary; Renal Insufficiency, Chronic | Details |
| Eneboparatide | AZP-3601 | Phase 3 Clinical | Harvard Medical School, Massachusetts General Hospital | Endocrine System Diseases; Hypoparathyroidism; Parathyroid Diseases | Details |
| Teriparatide transdermal (Corium International) | Phase 2 Clinical | Corium International Inc | Osteoporosis | Details | |
| Teriparatide transdermal (Zosano Pharma) | B-106; B-104; ZP-PTH; ThPTH (1-34); TH-0229 | Phase 2 Clinical | Zosano Pharma Corp | Osteoporosis; Osteoporosis, Postmenopausal | Details |
| KUR-113 | KUR-113; I-040202; Fibrin-PTH | Phase 2 Clinical | Kuros Biosciences | Intervertebral Disc Degeneration; Spinal Diseases; Wounds and Injuries | Details |
| T3-sulfate (Bracco SpA) | Phase 2 Clinical | Bracco Spa | Hypothyroidism | Details | |
| Recombinant Human Parathyroid Hormone (1-34)(Shanghai Celgen Biopharmaceuticals) | Phase 2 Clinical | Shanghai Celgen Bio-Pharmaceutical Co Ltd | Osteoporosis | Details | |
| KUR-111 | I-0401; KUR-111 | Phase 2 Clinical | Kuros Biosciences | Fractures, Bone | Details |
| ST-1891 | ST-1891 | Phase 2 Clinical | Sention Therapeutics LLC | Hypothyroidism | Details |
| Teriparatide oral (Entera Bio) | EB612; EB-612; EB-613; PTH 1-34; EBP-05; EBP05; hPTH(1-34) (Entera Bio); PTH-1-34 | Phase 2 Clinical | Entera Bio Ltd | Drug-Related Side Effects and Adverse Reactions; Fractures, Stress; Hypoparathyroidism; Osteoporosis | Details |
| EXT-608 | EXT-608 | Phase 2 Clinical | Extend Biosciences Inc | Hypoparathyroidism | Details |
| Canvuparatide | MBX-2109; MBX 2109 | Phase 2 Clinical | MBX Biosciences Inc | Hypoparathyroidism; Renal Insufficiency | Details |
| Teriparatide biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Osteoporosis | Details | |
| Hemoparatide | hPTH-137 | Phase 1 Clinical | Pharis Biotec | Psoriasis | Details |
| Tripatide (Yunnan First Applied Pharma) | Phase 1 Clinical | Yunnan First Applied Pharmaceutical Industry | Osteoporosis | Details | |
| SEP-786 | SEP-786 | Phase 1 Clinical | Septerna Inc | Hypoparathyroidism | Details |
| Teriparatide biosimilar (Shanghai Duomirui) | Phase 1 Clinical | Shanghai Duomirui Biotechnology Co Ltd | Osteoporosis | Details | |
| Teriparatide biosimilar (Wuxi Hebang) | Phase 1 Clinical | Wuxi Hebang Biotechnology Co Ltd | Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures | Details | |
| RT-102(Rani) | RT-102 | Phase 1 Clinical | Rani Therapeutics Holdings Inc | Osteoporosis | Details |
| Parathyroid hormone 1-84(Sichuan Luzhou Buchang Biopharmaceutical) | Phase 1 Clinical | Sichuan Luzhou Buchang Biopharmaceutical Co Ltd | Hypocalcemia | Details | |
| MT-1009 | MT-1009 | Phase 1 Clinical | Shaanxi Micot Pharmaceutical Technology Co Ltd | Glucocorticoid-induced osteoporosis; Osteoporosis | Details |
| BMD-1221 | BMD-1221 | Clinical | University Of Arkansas System | Fractures, Bone | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Palopegteriparatide | ACP-014; ACP014; ACP 014 | Approved | Ascendis Pharma | TransCon, YORVIPATH | EU | Hypoparathyroidism | Ascendis Pharma Bone Diseases As, Ascendis Pharma | 2023-11-17 | Endocrine System Diseases; Hypoparathyroidism; Parathyroid Diseases | Details |
| Teriparatide biosimilar (Biosidus) | rhPTH (1-34) (Biosidus) | Approved | Biosidus | Osteofortil | Argentina | Osteoporosis | Biosidus | 2012-08-01 | Osteoporosis | Details |
| Teriparatide biosimilar (Amega Biotech) | rhPTH (1-34) (Amega Biotech) | Approved | Amega Biotech | Osteoporosis | Details | |||||
| Teriparatide biosimilar (Pfenex) | rhPTH (1-34) (Pfenex); PF-708 | Approved | Pfenex Biopharmaceuticals Inc | Bonsity, Qutavina | United States | Glucocorticoid-induced osteoporosis; Osteoporosis, Postmenopausal; Osteoporosis | Alvogen | 2019-10-04 | Glucocorticoid-induced osteoporosis; Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Teriparatide | LY 333334; hPTH-1-34; MN-10T | Approved | Eli Lilly And Company | Forteo, Forsteo, 复泰奥 | United States | Osteoporosis | Eli Lilly And Company | 2002-11-26 | Ankle Fractures; Anorexia Nervosa; Back Pain; Bone Diseases, Metabolic; Cartilage Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Colles' Fracture; Femoral Neck Fractures; Fractures, Bone; Humeral Fractures; Hyperparathyroidism, Secondary; Hypocalcemia; Hypoparathyroidism; Menopausal symptoms; Osteoarthritis, Knee; Osteoporosis; Osteoporosis, Postmenopausal; Periodontitis; Spinal Cord Injuries; Spinal Fractures | Details |
| Parathyroid hormone (Shire) | SHP-634; ALX-111; 423562; NPSP-795; rhPTH (1-84); SHP-635; rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558 | Approved | Shire | Natpara, Preotact, Natpar | United States | Hypoparathyroidism | Nps Pharmaceuticals, Inc | 2006-04-24 | Autosomal Dominant Hypocalcemia Type 1; Bone Diseases, Endocrine; Hyperparathyroidism; Hypocalcemia; Hypoparathyroidism; Osteoporosis; Osteoporosis, Postmenopausal; Plaque psoriasis | Details |
| Teriparatide biosimilar (Intas Pharmaceuticals) | rhPTH (1-34) (Intas Pharmaceuticals); INTG8; INTG-8 | Approved | Intas Biopharmaceuticals | Terifrac | India | Osteoporosis | Intas Biopharmaceuticals | 2010-12-01 | Osteoporosis | Details |
| Teriparatide biosimilar (Gedeon Richter) | rhPTH (1-34) (Gedeon Richter) | Approved | Gedeon Richter Plc | Terrosa | EU | Osteoporosis | Gedeon Richter Plc | 2017-01-04 | Fractures, Stress; Osteoporosis | Details |
| Teriparatide biosimilar (Salubris) | SAL056; G56-W1; SAL-001 | Approved | Shenzhen Salubris Pharmaceuticals Co Ltd | 欣复泰 | Mainland China | Osteoporosis, Postmenopausal | Suzhou Genemen Biotech Co Ltd | 2019-09-29 | Osteoporosis, Postmenopausal | Details |
| Teriparatide biosimilar (USV) | Approved | USV Pvt Ltd | Osteoporosis | Details | ||||||
| Teriparatide biosimilar (Strides Pharma) | SBL-001 | Approved | Strides Pharma | Kauliv | EU | Osteoporosis; Osteoporosis, Postmenopausal | Strides Pharma (Cyprus) Ltd | 2023-01-12 | Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Teriparatide biosimilar (STADA Arzneimittel AG) | rhPTH (1-34) (STADA Arzneimittel AG) | Approved | Stada Arzneimittel Ag | Movymia | EU | Osteoporosis | Stada Arzneimittel Ag | 2017-01-11 | Osteoporosis | Details |
| Teriparatide biosimilar (Teva) | Approved | Teva | Ireland | Osteoporosis | Teva Bv | 2018-06-22 | Osteoporosis | Details | ||
| Teriparatide biosimilar (Almaject) | Approved | Almaject Inc | United States | Osteoporosis; Osteoporosis, Postmenopausal | Almaject Inc | 2024-06-04 | Osteoporosis; Osteoporosis, Postmenopausal | Details | ||
| Recombinant parathyroid hormone biosimilar(Chongqing Fujin Biological Medicine) | Approved | Chongqing Fujin Biological Medicine Co Ltd | Details | |||||||
| Recombinant Human Parathyroid Hormone (1-34), Shanghai Fosunpharma | Approved | Details | ||||||||
| Teriparatide acetate | hPTH (1-34) acet. H2O; AK-159; MN-10-T | Approved | Union Square Ventures Llc | Parathar, Teribone | Japan | Hypocalcemia; Osteoporosis | null | 1987-03-31 | Hypocalcemia; Osteoporosis | Details |
| Teriparatide biosimilar (Theramex) | Approved | Theramex Ireland Ltd | Livogiva | EU | Osteoporosis | Theramex Ireland Ltd | 2020-08-27 | Osteoporosis | Details | |
| Teriparatide biosimilar (Shanghai United Cell ） | Approved | Shanghai United Cell Biotechnology Co Ltd | Mainland China | Osteoporosis | Shanghai United Cell Biotechnology Co Ltd | 2017-03-22 | Osteoporosis | Details | ||
| Teriparatide biosimilar (Beijing Bokangjian Gene) | Approved | Beijing Genetech Pharmaceutical Co Ltd | 博固泰 | Mainland China | Osteoporosis | Beijing Genetech Pharmaceutical Co Ltd | 2024-01-16 | Osteoporosis; Osteoporosis, Postmenopausal | Details | |
| Teriparatide biosimilar (Virchow/Sun) | rhPTH (1-34) (Virchow/Sun) | Approved | Sun Pharmaceutical Industries Ltd, Virchow Group | Bonista, Osteotide | EU | Osteoporosis; Osteoporosis, Postmenopausal | Sun Pharmaceutical Industries (Europe) Bv | Osteoporosis; Osteoporosis, Postmenopausal | Details | |
| Teriparatide biosimilar (CinnaGen) | rhPTH (1-34) (CinnaGen) | Approved | Cinnagen | CinnoPar | Iran | Osteoporosis | Cinnagen | 2013-01-01 | Osteoporosis | Details |
| Teriparatide biosimilar (Zydus Cadila) | rhPTH (1-34) (Zydus Cadila) | Approved | Zydus Cadila | India | Osteoporosis | Zydus Cadila | 2014-01-01 | Osteoporosis | Details |
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main